BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 431 filers reported holding BIO-TECHNE CORP in Q4 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,214,317 | -17.8% | 32,530 | -1.5% | 0.02% | -12.0% |
| Q2 2023 | $2,694,851 | +10.8% | 33,013 | +0.7% | 0.02% | +4.2% |
| Q1 2023 | $2,432,616 | +131535.1% | 32,789 | +47.0% | 0.02% | -14.3% |
| Q4 2022 | $1,848 | -99.9% | 22,302 | +301.8% | 0.03% | +12.0% |
| Q3 2022 | $1,576,000 | -12.2% | 5,551 | +7.1% | 0.02% | -13.8% |
| Q2 2022 | $1,796,000 | -18.6% | 5,181 | +1.7% | 0.03% | -3.3% |
| Q1 2022 | $2,207,000 | -21.2% | 5,096 | -5.9% | 0.03% | -11.8% |
| Q4 2021 | $2,800,000 | -3.8% | 5,413 | -9.9% | 0.03% | -5.6% |
| Q3 2021 | $2,912,000 | -77.7% | 6,009 | -79.3% | 0.04% | -76.3% |
| Q2 2021 | $13,050,000 | +17.9% | 28,983 | -0.0% | 0.15% | +10.9% |
| Q1 2021 | $11,071,000 | +8.8% | 28,986 | -9.6% | 0.14% | +7.0% |
| Q4 2020 | $10,177,000 | +9.9% | 32,051 | -14.3% | 0.13% | +2.4% |
| Q3 2020 | $9,262,000 | +16.1% | 37,386 | +23.8% | 0.12% | -1.6% |
| Q2 2020 | $7,975,000 | +29.9% | 30,199 | -6.8% | 0.13% | +13.4% |
| Q1 2020 | $6,141,000 | +7.3% | 32,386 | +24.2% | 0.11% | +28.7% |
| Q4 2019 | $5,722,000 | +12.9% | 26,069 | +0.6% | 0.09% | +8.8% |
| Q3 2019 | $5,069,000 | -5.4% | 25,908 | +0.8% | 0.08% | -3.6% |
| Q2 2019 | $5,359,000 | +5.3% | 25,703 | +0.2% | 0.08% | +2.5% |
| Q1 2019 | $5,091,000 | +42.3% | 25,643 | +3.8% | 0.08% | +28.6% |
| Q4 2018 | $3,577,000 | -26.2% | 24,714 | +4.1% | 0.06% | -6.0% |
| Q3 2018 | $4,846,000 | +35.1% | 23,740 | -2.1% | 0.07% | +36.7% |
| Q2 2018 | $3,588,000 | -4.2% | 24,251 | -2.2% | 0.05% | -2.0% |
| Q1 2018 | $3,747,000 | +14.2% | 24,808 | -2.0% | 0.05% | +22.0% |
| Q4 2017 | $3,281,000 | -0.4% | 25,324 | -7.1% | 0.04% | -2.4% |
| Q3 2017 | $3,295,000 | +2.9% | 27,255 | -0.0% | 0.04% | 0.0% |
| Q2 2017 | $3,203,000 | +16.6% | 27,257 | +0.9% | 0.04% | +16.7% |
| Q1 2017 | $2,746,000 | -1.9% | 27,014 | -0.7% | 0.04% | -2.7% |
| Q4 2016 | $2,798,000 | -10.1% | 27,212 | -4.2% | 0.04% | -11.9% |
| Q3 2016 | $3,111,000 | -3.1% | 28,412 | -0.1% | 0.04% | -2.3% |
| Q2 2016 | $3,209,000 | +14.1% | 28,454 | -4.3% | 0.04% | +19.4% |
| Q1 2016 | $2,812,000 | +1.3% | 29,748 | -3.5% | 0.04% | +5.9% |
| Q4 2015 | $2,775,000 | -2.3% | 30,835 | +0.4% | 0.03% | -5.6% |
| Q3 2015 | $2,841,000 | -8.7% | 30,725 | -2.8% | 0.04% | 0.0% |
| Q2 2015 | $3,112,000 | -7.2% | 31,607 | -5.5% | 0.04% | -2.7% |
| Q1 2015 | $3,354,000 | +8.8% | 33,445 | +0.2% | 0.04% | +8.8% |
| Q4 2014 | $3,084,000 | – | 33,378 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 275,000 | $18,719,250 | 20.14% |
| Montanaro Asset Management Ltd | 408,800 | $27,827,016 | 4.90% |
| Sandhill Capital Partners LLC | 613,061 | $41,731,091 | 3.90% |
| Pembroke Management, LTD | 365,611 | $24,887,141 | 3.40% |
| DF DENT & CO INC | 3,349,047 | $227,969,648 | 3.34% |
| Brown Capital Management | 3,158,004 | $214,965,332 | 3.30% |
| Ownership Capital B.V. | 1,786,273 | $121,591,603 | 3.05% |
| STONE RUN CAPITAL, LLC | 86,335 | $5,876,823 | 2.88% |
| Jackson Square Partners, LLC | 1,260,547 | $85,805,434 | 2.87% |
| Summit Creek Advisors LLC | 284,681 | $19,378,236 | 2.64% |